WallStreetZenWallStreetZen

NASDAQ: TLRY
Tilray Brands Inc Stock

$1.84+0.12 (+6.98%)
Updated Apr 23, 2024
TLRY Price
$1.84
Fair Value Price
N/A
Market Cap
$1.42B
52 Week Low
$1.50
52 Week High
$3.40
P/E
-4.18x
P/B
0.42x
P/S
1.76x
PEG
N/A
Dividend Yield
N/A
Revenue
$743.25M
Earnings
-$351.95M
Gross Margin
28%
Operating Margin
-41.82%
Profit Margin
-47.4%
Debt to Equity
0.26
Operating Cash Flow
-$18M
Beta
1.56
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

TLRY Overview

Tilray Brands, Inc. engages in the research, cultivation, production, marketing, and distribution of medical cannabis products in Canada, the United States, Europe, Australia, New Zealand, Latin America, and internationally. The company operates through four segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. It offers medical and adult-use cannabis products, including GMP-certified flowers, oils, vapes, edibles, and topicals; purchases and resells pharmaceutical and wellness products; and produces, markets, sells, and distributes beverage alcohol products, and hemp-based food and other wellness products. The company offers its products under the Tilray, Aphria, Broken Coast, Symbios, B!NGO, The Batch, P'tite Pof, Dubon, Good Supply, Solei, Chowie Wowie, Canaca, RIFF, SweetWater, Breckenridge Distillery, Alpine Beer Company, and Green Flash brands. It sells its products to retailers, wholesalers, patients, physicians, hospitals, pharmacies, researchers, and governments, as well as direct to consumers. The company was formerly known as Tilray, Inc. Tilray Brands, Inc. is headquartered in Leamington, Canada.

Zen Score

Industry Average (25)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how TLRY scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

TLRY is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
TLRY is good value based on its book value relative to its share price (0.42x), compared to the US Drug Manufacturers - Specialty & Generic industry average (2.07x)
P/B vs Industry Valuation
TLRY is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more TLRY due diligence checks available for Premium users.

Be the first to know about important TLRY news, forecast changes, insider trades & much more!

TLRY News

Valuation

TLRY fair value

Fair Value of TLRY stock based on Discounted Cash Flow (DCF)
Price
$1.84
Fair Value
$2.50
Undervalued by
26.38%
TLRY is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

TLRY price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-4.18x
Industry
46.85x
Market
41.92x

TLRY price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
0.42x
Industry
2.07x
TLRY is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

TLRY's financial health

Profit margin

Revenue
$188.3M
Net Income
-$92.7M
Profit Margin
-49.2%
TLRY's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
TLRY's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$4.2B
Liabilities
$869.8M
Debt to equity
0.26
TLRY's short-term assets ($631.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
TLRY's short-term assets ($631.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
TLRY's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
TLRY's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$15.4M
Investing
$28.1M
Financing
-$10.9M
TLRY's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

TLRY vs Pharmaceutical Stocks

TickerMarket Cap1d %P/EP/B
TLRY$1.42B+6.98%-4.18x0.42x
ANIP$1.39B+0.79%76.91x3.22x
DVAX$1.54B-0.68%-235.20x2.47x
IRWD$1.30B+3.10%-1.29x-3.76x
TARO$1.59B-0.07%34.61x0.89x

Tilray Brands Stock FAQ

What is Tilray Brands's quote symbol?

(NASDAQ: TLRY) Tilray Brands trades on the NASDAQ under the ticker symbol TLRY. Tilray Brands stock quotes can also be displayed as NASDAQ: TLRY.

If you're new to stock investing, here's how to buy Tilray Brands stock.

What is the 52 week high and low for Tilray Brands (NASDAQ: TLRY)?

(NASDAQ: TLRY) Tilray Brands's 52-week high was $3.40, and its 52-week low was $1.50. It is currently -45.88% from its 52-week high and 22.67% from its 52-week low.

How much is Tilray Brands stock worth today?

(NASDAQ: TLRY) Tilray Brands currently has 774,028,558 outstanding shares. With Tilray Brands stock trading at $1.84 per share, the total value of Tilray Brands stock (market capitalization) is $1.42B.

Tilray Brands stock was originally listed at a price of $22.39 in Jul 19, 2018. If you had invested in Tilray Brands stock at $22.39, your return over the last 5 years would have been -91.78%, for an annualized return of -39.33% (not including any dividends or dividend reinvestments).

How much is Tilray Brands's stock price per share?

(NASDAQ: TLRY) Tilray Brands stock price per share is $1.84 today (as of Apr 23, 2024).

What is Tilray Brands's Market Cap?

(NASDAQ: TLRY) Tilray Brands's market cap is $1.42B, as of Apr 24, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Tilray Brands's market cap is calculated by multiplying TLRY's current stock price of $1.84 by TLRY's total outstanding shares of 774,028,558.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.